Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296590 · ClinicalTrials.gov registry record
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
A clinical trial of Sepsis and Septic Shock, sponsored by Henry Ford Health System.
- Active
- Registry status
- 50,000
- Enrollment target
- 1
- Study location
NCT05296590: Active study of Sepsis and Septic Shock, sponsored by Henry Ford Health System.
NCT05296590 is a study of Sepsis and Septic Shock that is active but no longer recruiting, run by Henry Ford Health System. The registered enrollment target is 50,000 participants, above the 6,009-participant average among 90 other Sepsis trials with a reported enrollment target (732% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05296590, a study of Sepsis and Septic Shock, is active but no longer recruiting, sponsored by Henry Ford Health System.
- ACTIVE NOT RECRUITING
- Registry status
- 50,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will evaluate the usefulness of Monocyte Distribution Width (MDW) for the diagnosis of blood culture positivity (BSI) in patients in the Emergency Department (ED) and reevaluate the usefulness of MDW in patients with BSI and sepsis. Consequently, if MDW indicate a high likelihood of bacteremia antibiotic management in patients with suspected bacterial infections will be changed and aid appropriate antibiotic administration.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Monocyte Distribution Width (MDW) , observation
Study Locations (1)
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50,000 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2026-06 |
What the registry record for NCT05296590 still lists
NCT05296590 is an observational study that tracks outcomes without assigning an intervention. Its 50,000 participants enrollment target places it among the larger protocols in the corpus, above the 6,009-participant average among 90 other Sepsis trials with a reported enrollment target (732% higher).
The record links to 7 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Monocyte Distribution Width (MDW) , observation is the first listed.
NCT05296590 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05296590 about?
NCT05296590 is a clinical study titled "Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia". This project will evaluate the usefulness of Monocyte Distribution Width (MDW) for the diagnosis of blood culture positivity (BSI) in patients in the Emergency Department (ED) and reevaluate the usefulness of MDW in patients with BSI and sepsis. Consequently, if MDW indicate a high likelihood of bac...
What is the current status of trial NCT05296590?
This trial is currently active not recruiting. The enrollment target is 50,000 participants. The study started on 2021-07-01. Estimated completion is 2026-06.
What conditions does trial NCT05296590 study?
This clinical trial studies the following conditions: Sepsis, Septic Shock, Bacteremia, Severe Sepsis, Continuity of Patient Care.
What interventions are being tested in trial NCT05296590?
The interventions under investigation include: Monocyte Distribution Width (MDW) , observation (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05296590?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296590 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05296590's enrollment target sits among peer trials
50,000 3rd of 90 higher than 88 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- NCT03452774 · 50,000 participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- NCT04629586 · 50,000 participants
The T1D Exchange Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI